Outcomes of anti-PD-L1 blockades plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) with brain metastasis (BM).

被引：0
|
作者：
Tian, Yaru
Ma, Ji
Zhu, Hui
Yu, Jinming
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20607
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)
    Paz-Ares, L.
    Juan-Vidal, O.
    Carcereny, E.
    Greillier, L.
    Navarro, A.
    Bennouna, J.
    Santoro, A.
    Berardi, R.
    Besse, B.
    Salvagni, S.
    Gonzalez, H.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    Ponce, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S482 - S483
  • [22] Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S509 - S510
  • [23] Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis
    Chen, Hanxiao
    Ma, Xiangjuan
    Liu, Jie
    Yang, Yu
    He, Yanhui
    Fang, Yong
    Wang, Liping
    Fang, Jian
    Zhao, Jun
    Zhuo, Minglei
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1664 - 1673
  • [24] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes
    Schulz, C.
    Chen, Y.
    Paz-Ares, L. G.
    Dvorkin, M.
    Trukhin, D.
    Reinmuth, N.
    Garassino, M. C.
    Statsenko, G.
    Voitko, O.
    Hochmair, M. J.
    Ozguroglu, M.
    Verderame, F.
    Havel, L.
    Losonczy, G.
    Conev, N.
    Hotta, K.
    Ji, J. H.
    Broadhurst, H.
    Byrne, N.
    Thiyagarajah, P.
    Goldman, J. W.
    Alt, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 144 - 145
  • [25] First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
    Katsuyuki Hotta
    Makoto Nishio
    Haruhiro Saito
    Isamu Okamoto
    Yasuharu Nakahara
    Hidetoshi Hayashi
    Manabu Hayama
    Peter Laud
    Haiyi Jiang
    Luis Paz-Ares
    Koichi Azuma
    International Journal of Clinical Oncology, 2021, 26 : 1073 - 1082
  • [26] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
    Daniel, D.
    Kuchava, V.
    Bondarenko, I.
    Ivashchuk, O.
    Spigel, D.
    Dasgupta, A.
    Reddy, S.
    Melkadze, T.
    Jaal, J.
    Kudaba, I.
    Hart, L.
    Matitashvili, A.
    Koynov, K. D.
    Yang, Z.
    Wolfe, S. G.
    Malik, R.
    Morris, S. R.
    Antal, J. M.
    Goldschmidt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
  • [27] First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
    Hotta, Katsuyuki
    Nishio, Makoto
    Saito, Haruhiro
    Okamoto, Isamu
    Nakahara, Yasuharu
    Hayashi, Hidetoshi
    Hayama, Manabu
    Laud, Peter
    Jiang, Haiyi
    Paz-Ares, Luis
    Azuma, Koichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (06) : 1073 - 1082
  • [28] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
    Horn, L.
    Mansfield, A. S.
    Szczesna, A.
    Havel, L.
    Krzakowski, M.
    Hochmair, M. J.
    Huemer, F.
    Losonczy, G.
    Johnson, M. L.
    Nishio, M.
    Reck, M.
    Mok, T.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Ding, B.
    Lopez-Chavez, A.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
  • [29] Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
    Zhang, Longfeng
    Hang, Yongfu
    Liu, Maobai
    Li, Na
    Cai, Hongfu
    FRONTIERS IN ONCOLOGY, 2020, 10
12345